Quantum Biopharma (NASDAQ:QNTM) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Quantum Biopharma (NASDAQ:QNTMFree Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Quantum Biopharma Price Performance

NASDAQ QNTM opened at $15.45 on Friday. The company has a market cap of $41.81 million, a PE ratio of -1.00 and a beta of 0.55. The stock’s 50 day simple moving average is $9.08 and its 200-day simple moving average is $6.57. Quantum Biopharma has a 1-year low of $2.70 and a 1-year high of $18.00.

Quantum Biopharma (NASDAQ:QNTMGet Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($1.04). The firm had revenue of $2.09 million during the quarter, compared to analyst estimates of $2.09 million. On average, equities research analysts anticipate that Quantum Biopharma will post -3.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Quantum Biopharma

A hedge fund recently raised its stake in Quantum Biopharma stock. AdvisorShares Investments LLC grew its position in Quantum Biopharma Ltd. (NASDAQ:QNTMFree Report) by 163.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,078 shares of the company’s stock after acquiring an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned about 3.60% of Quantum Biopharma worth $254,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

(Get Free Report)

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.

See Also

Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.